2.28
+10.14%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Niagen Bioscience
From its filings with the US Securities and Exchange Commission
Niagen Bioscience is based in Los Angeles, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NAGE. The SEC classifies its business as medicinal chemicals & botanical products. In the fiscal year to 31 December 2025, it reported revenue of $129.4m and net income of $17.4m. At that date it held total assets of $106.4m and shareholders' equity of $76.5m.
On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (Cody) entered into an Agreement and Plan of Merger (Merger Agreement), by and among Cody, CDI Acquisition, Inc., a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation. On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation. On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq).
Effective March 19, 2025, the Company changed its name to “Niagen Bioscience, Inc.”. In connection with the Company’s new name, the Company changed the ticker symbol for the Company’s common stock on Nasdaq, to “NAGE”.
We are a global bioscience company dedicated to promoting healthy aging. Our team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism and is present in every cell of the human body. NAD+ levels naturally decline with age, by up to 65% between ages 30 and 70, and can also be impacted by poor diet, excess alcohol consumption, and certain disease states. Increasing NAD+ levels through NAD+ precursors, calorie restriction, or moderate exercise has been shown to support healthy cellular function. We are at the forefront of developing and commercializing effective methods to support NAD+ levels and promote healthy aging.
Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 25 Jun 2007
- Employees
- 110
- Website
- chromadex.com/default.aspx ↗
- Head office
- 10900 WILSHIRE BLVD, LOS ANGELES, CA, 90024
- Incorporated in
- DE
- Classification
- Medicinal Chemicals & Botanical Products
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Frank JakschChairman of the Board, since 2000$106,319
- Mr. Robert FriedChief Executive Officer, Director, since 2015$1.2m
- Mr. Ozan PamirChief Financial Officer$461,641
- Mr. Carlos LopezSenior Vice President, General Counsel$347,638
- Mr. Steven RubinLead Independent Director$131,319
- Ms. Ann CohenIndependent Director$103,819
- Mr. Gary NgIndependent Director$83,819
- Ms. Kristin PatrickIndependent Director$96,319
- Mr. Hamed ShahbaziIndependent Director$81,319
- Ms. Wendy YuIndependent Director$81,319
- Mr. Ben ShamsianInvestor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 61
- Social
- 39
- Governance
- 63
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Chromadex Corp has a strong intellectual property portfolio, which provides a competitive advantage in the market.
- The company has optimized its manufacturing processes, allowing for efficient production and cost-effective operations.
- Chromadex Corp has established strategic partnerships with reputable organizations, enabling access to new markets and resources.
Weaknesses
- The company heavily relies on a few key customers, making its revenue vulnerable to fluctuations in their demands.
- Chromadex Corp has limited brand recognition, which may hinder its ability to attract new customers and expand market share.
- The company faces regulatory risks due to the nature of its products, potentially leading to compliance challenges.
Opportunities
- There is a growing demand for health and wellness products, presenting an opportunity for Chromadex Corp to expand its customer base.
- The company can leverage advancements in technology to develop innovative products that cater to emerging trends in the market.
- Expansion into international markets provides Chromadex Corp with the chance to reach a wider audience and diversify its revenue streams.
Threats
- Intense competition in the industry poses a threat to Chromadex Corp's market share and pricing power.
- Economic downturns and fluctuations in exchange rates may impact the company's profitability, particularly in global operations.
- The company is subject to potential lawsuits and legal challenges, especially related to product safety and intellectual property infringements.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.